- Romidepsin for peripheral T-cell lymphomaAmit Khot
Peter MacCallum Cancer Centre, Division of Cancer Medicine, Locked Bag 1, A Beckett St, VIC 8006, Australia
Expert Rev Hematol 6:351-9. 2013....
- A risk-adapted protocol for delayed administration of filgrastim after high-dose chemotherapy and autologous stem cell transplantationAmit Khot
Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Clin Lymphoma Myeloma Leuk 13:42-7. 2013..We prospectively explored a strategy that used prophylactic delayed filgrastim only in patients with risk factors...
- Panobinostat in lymphoid and myeloid malignanciesAmit Khot
Department of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Expert Opin Investig Drugs 22:1211-23. 2013..Activity has been demonstrated in hematological diseases, such as cutaneous T-cell lymphoma (CTCL), Hodgkin lymphoma (HL), myeloma and myeloid malignancies...
- Romidepsin for cutaneous T-cell lymphomaH Miles Prince
Department of Haematology, Peter MacCallum Cancer Centre, Division Cancer Medicine, St Andrew s Place, East Melbourne, Australia
Future Oncol 9:1819-27. 2013..Romidepsin provides a subset of patients with an opportunity for prolonged clinical responses with a tolerable side-effect profile...